Isarna Therapeutics GmbH

Quick facts

Phase 2 pipeline

• AP 12009 10 µM · Oncology
  AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity.
• AP 12009 80 µM · Oncology
  AP 12009 80 µM is an anti-PD-1 monoclonal antibody.
• temozolomide or PCV

Phase 1 pipeline

• AP 12009
• TGF-β2 antisense oligonucleotide

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Isarna Therapeutics GmbH portfolio CI brief
• Isarna Therapeutics GmbH pipeline updates RSS